ClinicalTrials.gg
CompletedNCT06486285Updated Jul 18, 2025

Auditory-Cognitive Dual-Task Intervention for Older Adults With Hearing Loss

An interventional study of Auditory-cognitive dual-task training (ACDT) in Age-related Hearing Loss, Cognitive Decline and Loneliness, sponsored by The Hong Kong Polytechnic University. Completed at 1 site in Hong Kong. Open to participants aged 60 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years to 100 Years
Sex
All
01

Study summary

Background: Age-related hearing loss (ARHL) is a common and irreversible condition that has been recently associated with cognitive decline and dementia. Hence, if ARHL is treated earlier, the risk of dementia might decrease. However, in China, only 0.8% of older adults with hearing loss wore hearing aids, and over two-thirds (67.5%) of older adults with ARHL in Hong Kong had either been formally diagnosed or treated. There is also limited information on the feasibility and efficacy of hearing loss interventions for older people in Hong Kong. It is important to develop hearing loss interventions that have the potential to improve cognitive functions among older people.

Aims: This study aims to assess the feasibility and acceptability of a new auditory-cognitive dual-task intervention (ACDT) for community-dwelling older adults with hearing loss, and to examine the preliminary efficacy of ACDT on their cognitive function.

Study design and Methods: This is mixed-model design, using a 2-arm, parallel-group, single-blinded, pilot randomized controlled trial (pilot RCT). A total of 60 community-dwelling older adults in Hong Kong who have mild to moderate hearing loss and normal cognitive performance will be recruited. Participants will be randomly assigned to the auditory-cognitive dual-task intervention group (ACDTG), and control group with no specific intervention (a "wait list" group) (CG). Each ACDTG participant will receive the intervention for 12 weeks (5 days x 60-min sessions per day). All participants in all groups will be assessed for cognitive function (primary outcome), social isolation, and loneliness, and hearing at baseline (T0), and after the intervention (T1). Post-intervention interviews will be conducted to obtain perspectives of participants in the ACDTG on the feasibility and acceptability of the ACDT intervention.

Data analysis: Participant characteristics and outcome variables will be analysed through descriptive statistics. Differences in cognition score and other outcomes across time points among the participant groups will be measured by Generalized Estimating Equations (GEE). The statistical software package IBM SPSS version 26.0 will be used. Content analysis will used to analyse the post-intervention interviews.

Expected results: ACDT will be feasible for implementation and acceptable for community-dwelling older adults with hearing loss. While ACDT will not be able to improve underlying hearing in ARHL, it will be more effective on improving participants' cognitive function, social engagement and loneliness, and ability in information processing, interpretation and communication, than CG.

02

Conditions studied

  • Age-related Hearing Loss
  • Cognitive Decline
  • Loneliness
  • Social Isolation
03

In context

Presbycusis

66 studies on the registry are indexed under Presbycusis; 21 are open to participants now.

This study's enrollment of 60 is close to the median of 60 across 45 interventional studies indexed under Presbycusis.

Browse Presbycusis studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 679 studies on the registry; 257 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged 60 and above living in the community;
  • have mild to moderate hearing loss with a pure-tone average (PTA) between 25 and 60 dB in both ears (average hearing threshold at 0.5, 1, 2, and 4 kHz measuring by audiometer with headphones in a quite listening environment, no hearing aid use within the past 6 months;
  • with normal cognitive performance ( score ≥26); and
  • are willing to and capable of providing and complying with study procedures.

Exclusion criteria

Exclusion Criteria:

  • have a history of psychosis, mania, bipolar disorder, substance use disorder or have current suicidal ideation;
  • with severe or unstable medical illness, significant retrocochlear pathology or organic lesion responsible for hearing loss;
  • a diagnosis of probable Alzheimer's disease, vascular dementia, FTD, or Parkinson's Disease; and
  • taking medications such as antidepressants, sedatives, or antiepileptics that may affect cognition.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Auditory-cognitive dual-task training (ACDT)

    The new auditory-cognitive dual-task training (ACDT) is a 12-week program (5 times/week, 60 minutes per day). Auditory training (i.e., speech-in-noise training, rapid speech training and competing speaking training) will be incorporated with cognitive exercises involving the domains of executive function, perceptual-motor ability, memory, and complex attention.

    Behavioral: Auditory-cognitive dual-task training (ACDT)

  • No intervention
    Control

    no specific treatment. This is a "wait list" group, participants can choose either the Auditory-cognitive dual-task training or the cognitive training after 12 weeks.

Interventions

  • BehavioralAuditory-cognitive dual-task training (ACDT)

    The components of auditory training are designed based on an auditory training and aural rehabilitation program LACETM (Listening \& Communication Enhancement) developed by our study team member. The cognitive training was developed and tested feasible and valid in our study team's previous dual-task Zumba cognitive training.

06

What researchers measure

Primary outcomes

  1. Global cognition

    Global cognition will be measured by the Hong Kong-Montreal Cognitive Assessment (HK-MoCA). MoCA measures multiple cognitive domains, including attention, orientation, concentration, language, memory, executive functions and visuo-spatial skills. MoCA ≥26 is considered as normal, while 22-26 refers to mild cognitive impairment.

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

Secondary outcomes

  1. Learning and memory

    The Chinese Auditory Verbal Learning Test will be used.

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

  2. Hearing

    will be measured by an audiometer with sound level meter (to measure ambient noise).

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

  3. Social isolation

    will be measured by validated abbreviated 6-item Chinese version of the Lubben Social Network Scale (LSNS), which was developed specifically for use among older adults and shown to be both reliable and valid.The total score is calculated by finding the sum of the all items. For the LSNS-R, the score ranges between 0 and 60, with a higher score indicating more social engagement. For the LSNS-6, the score ranges between 0 and 30, with a higher score indicating more social engagement.

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

  4. Loneliness

    will be measured by the 6-item De Jong Gierveld loneliness scale (Chinese version). The total score of the scale ranges from zero to six, with higher scores indicating greater feelings of loneliness. A cut-off score of two or more was used to indicate the presence of loneliness, as recommended by van Tilburg and De Jong Gierveld

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

  5. Hearing

    Chinese version of the Hearing Handicap Inventory for the Elderly and the five-point Communication Scale for Older Adults will be utilized. The questionnaire consists of 10 items-five social/situational items and five emotional response items-with a total score range of 0-40. A "YES" response receives four points, a "NO" response receives zero points, and a "SOMETIMES" response receives two points. The HHIE-S total scores were used to classify the results into three categories: 0 to 8 (no self-perceived hearing handicap), 10-24 (mild to moderate handicap), and 26-40 (severe handicap). According to the American Speech-Language-Hearing Association's proposed recommendations, a total HHIE-S score of 8 indicates the presence of a hearing handicap

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

  6. Attention or working memory

    will be measured by the digit span (forward and backward) and visual span (forward and backward) methods

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

  7. Information processing speed

    will be assessed by the performance on the Chinese Trail Making Test Part A

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

  8. Executive function

    Will be assessed by the Chinese Trail Making Test Part B

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

  9. Verbal fluency

    will be assessed by the category verbal fluency tests (animal, fruit, and vegetable)

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

  10. Motor skills

    will be evaluated by the grooved pegboard for both dominant hand and nondominant hand

    Time frame: will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)

07

Study locations

1 site
  • PolyU
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: Yes — Individual deidentified participant data (including data dictionaries) will be shared. The investigators will publish research findings in peer reviewed and international official journals without Individual identifiable participant information according to the ethical requirement. Individual deidentified participant dataset can be shared per request and approved by the research core team.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06486285
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Aug 1, 2024
Primary completion
Jun 30, 2025
Completion
Jul 1, 2025
Last update
Jul 18, 2025

Study contacts

Ivy Zhao, Dr
principal investigator · School of Nursing, the Hong Kong Polytechnic University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion